MCID: TNP001
MIFTS: 47

Tinea Pedis

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Tinea Pedis

MalaCards integrated aliases for Tinea Pedis:

Name: Tinea Pedis 12 43 15 17 71 32
Athlete's Foot 12 74 42 62
Dermatophytosis of Foot 12
Ringworm of Foot 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12403
ICD9CM 34 110.4
MeSH 43 D014008
SNOMED-CT 67 6020002
ICD10 32 B35.3
UMLS 71 C0040259

Summaries for Tinea Pedis

MedlinePlus : 42 Athlete's foot is a common infection caused by a fungus. It most often affects the space between the toes. Symptoms include itching, burning, and cracked, scaly skin between your toes. You can get athlete's foot from damp surfaces, such as showers, swimming pools, and locker room floors. To prevent it Keep your feet clean, dry, and cool Wear clean socks Don't walk barefoot in public areas Wear flip-flops in locker room showers Keep your toenails clean and clipped short Treatments include over-the-counter antifungal creams for most cases and prescription medicines for more serious infections. These usually clear up the infection, but it can come back. Centers for Disease Control and Prevention

MalaCards based summary : Tinea Pedis, also known as athlete's foot, is related to tinea unguium and dermatomycosis, and has symptoms including maceration, fissures and scaling. An important gene associated with Tinea Pedis is SQLE (Squalene Epoxidase), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and Tuberculosis. The drugs Naftifine and Luliconazole have been mentioned in the context of this disorder. Affiliated tissues include skin of foot, skin and testes.

Disease Ontology : 12 A dermatophytosis that results in fungal infection located in skin of foot, especially between the toes, has material basis in Trichophyton or has material basis in Epidermophyton and has symptom fissures, has symptom scaling, has symptom maceration, and eroded areas between the toes and on the plantar surface of the foot.

PubMed Health : 62 About athlete's foot: Many people will have athlete's foot at some time throughout their life. It is usually the gaps between the toes that are affected. Athlete's foot can normally be treated effectively with creams available from the pharmacy. To prevent athlete's foot from developing at all, it is important to keep your feet dry.

Wikipedia : 74 Athlete's foot, known medically as tinea pedis, is a common skin infection of the feet caused by fungus.... more...

Related Diseases for Tinea Pedis

Diseases related to Tinea Pedis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 tinea unguium 31.6 SQLE CARD9 B4GALNT2
2 dermatomycosis 31.0 SLA2 POLR2B B4GALNT2
3 tinea capitis 31.0 SQLE CARD9 B4GALNT2
4 tinea cruris 30.8 SQLE CYP51A1 CLEC6A CARD9 B4GALNT2
5 tinea corporis 30.7 SQLE CLEC6A CLEC4E CARD9 B4GALNT2
6 bursitis 30.7 PES1 HECTD4
7 tenosynovitis 30.5 PES1 HECTD4
8 superficial mycosis 30.5 ZNF347 CLEC7A CLEC6A B4GALNT2
9 nerve compression syndrome 30.5 PES1 HECTD4
10 cutaneous candidiasis 30.4 ZNF347 CLEC7A CARD9 B4GALNT2
11 oral candidiasis 30.3 CLEC7A CLEC6A CARD9
12 dermatophytosis 30.2 TRIM4 SQLE POLR2B HECTD4 CLEC7A CLEC6A
13 pityriasis versicolor 29.9 ZNF347 SQLE CLEC7A CLEC6A CLEC4E
14 nail disease 29.7 CLEC7A CLEC6A CLEC4E CARD9
15 tinea manuum 11.8
16 dermatitis 10.7
17 skin disease 10.7
18 keratosis 10.6
19 erythrasma 10.5
20 dermatitis, atopic 10.5
21 candidiasis 10.5
22 candida glabrata 10.5
23 bacterial infectious disease 10.4
24 erysipelas 10.4
25 pustulosis of palm and sole 10.4
26 psoriasis 10.4
27 de quervain disease 10.4 PES1 HECTD4
28 achilles bursitis 10.4 PES1 HECTD4
29 heel spur 10.4 PES1 HECTD4
30 tarsal tunnel syndrome 10.4 PES1 HECTD4
31 tibial neuropathy 10.4 PES1 HECTD4
32 patellar tendinitis 10.4 PES1 HECTD4
33 tendinitis 10.4 PES1 HECTD4
34 osgood-schlatter's disease 10.4 PES1 HECTD4
35 peroneal nerve paralysis 10.4 PES1 HECTD4
36 plantar fasciitis 10.4 PES1 HECTD4
37 mononeuritis of lower limb 10.4 PES1 HECTD4
38 patellofemoral pain syndrome 10.4 PES1 HECTD4
39 calcific tendinitis 10.4 PES1 HECTD4
40 exanthem 10.4
41 cellulitis 10.4
42 overgrowth syndrome 10.4
43 synostoses, tarsal, carpal, and digital 10.4 PES1 HECTD4
44 kohler's disease 10.4 PES1 HECTD4
45 lumbosacral lipoma 10.4 PES1 HECTD4
46 spastic hemiplegia 10.4 PES1 HECTD4
47 otomycosis 10.3 POLR2B B4GALNT2
48 epicondylitis 10.3 PES1 HECTD4
49 ichthyosis, congenital, autosomal recessive 9 10.3 PES1 HECTD4
50 external ear disease 10.3 POLR2B B4GALNT2

Comorbidity relations with Tinea Pedis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Hypertension, Essential
Peripheral Vascular Disease Tinea Manuum
Venous Insufficiency

Graphical network of the top 20 diseases related to Tinea Pedis:



Diseases related to Tinea Pedis

Symptoms & Phenotypes for Tinea Pedis

Symptoms:

12
  • maceration
  • fissures
  • scaling

UMLS symptoms related to Tinea Pedis:


fever, pruritus, exanthema

Drugs & Therapeutics for Tinea Pedis

PubMed Health treatment related to Tinea Pedis: 62

Athlete's foot can usually be treated effectively with creams, gels or sprays that are available from pharmacies without a prescription. These products contain an ingredient that stops the growth of the fungus or kills it. But the treatment does require some patience. Home remedies such as tea tree oil or foot baths containing herbal products are sometimes recommended. But there is no scientific that they are effective against athlete's foot. Tablets are also an option if athlete's foot cannot be successfully treated topically. But that is only rarely necessary and must be given careful consideration because the risk of side effects is higher.

Drugs for Tinea Pedis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naftifine Approved Phase 4 65472-88-0 73342 47641
2
Luliconazole Approved Phase 4 187164-19-8
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4 Gastrointestinal Agents Phase 4
5 Anti-Ulcer Agents Phase 4
6 Antacids Phase 4
7 Proton Pump Inhibitors Phase 4
8
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
9
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
10
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
11
Econazole Approved Phase 3 27220-47-9 3198
12
Ciclopirox Approved, Investigational Phase 3 29342-05-0 2749
13 Pharmaceutical Solutions Phase 3
14
Nitric Oxide Approved Phase 2 10102-43-9 145068
15
Bifonazole Approved, Investigational Phase 2 60628-96-8 2378
16
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
17
Racepinephrine Approved Phase 2 329-65-7 838
18
Ethanol Approved Phase 2 64-17-5 702
19
Terbinafine Approved, Investigational, Vet_approved Phase 2 91161-71-6 5402 1549008
20
Polihexanide Approved, Investigational Phase 2 28757-47-3
21 Neurotransmitter Agents Phase 2
22 Respiratory System Agents Phase 2
23 Anti-Asthmatic Agents Phase 2
24 Protective Agents Phase 2
25 Vasodilator Agents Phase 2
26 Autonomic Agents Phase 2
27 Free Radical Scavengers Phase 2
28 Bronchodilator Agents Phase 2
29 Antioxidants Phase 2
30 Anti-Inflammatory Agents Phase 2
31 Epinephryl borate Phase 2
32 Hypoglycemic Agents Phase 2
33 Disinfectants Phase 2
34 Biguanides Phase 2
35
Oxiconazole Approved Phase 1 64211-46-7, 64211-45-6 5361463
36
Glucosamine Approved, Investigational Phase 1 3416-24-8 439213
37
Butenafine Approved Phase 1 101828-21-1 2484
38
Bradykinin Investigational Phase 1 58-82-2 439201
39 omega-N-Methylarginine Phase 1
40 Kininogens Phase 1
41 Ginkgo Phase 1
42 Cytochrome P-450 CYP2C9 Inhibitors Phase 1
43 Anti-Infective Agents, Local Phase 1
44
Salicylic acid Approved, Investigational, Vet_approved 69-72-7 338
45
Benzoic acid Approved, Investigational 65-85-0 243
46
acetic acid Approved 64-19-7 176
47
carbamide peroxide Approved 124-43-6

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
2 An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
3 An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Completed NCT02394340 Phase 4 Omeprazole 40 mg;Luliconazole Cream 1%
4 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
5 Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
6 Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" Unknown status NCT01105013 Phase 3 Clotrimazole
7 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
8 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Interdigital Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
9 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
10 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
11 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
12 Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
13 A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
14 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
15 An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris Completed NCT01349998 Phase 3 Product 33525
16 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
17 A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
18 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
19 A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis Completed NCT03824912 Phase 3 Ketoconazole Cream 2%;Ketoconazole Cream 2% (G&W Laboratories Inc.);Placebo
20 A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis. Recruiting NCT04203342 Phase 3 Ketoconazole 2% Cream
21 Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis Recruiting NCT03320486 Phase 3 Dapaconazole;Ketoconazole
22 A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis Terminated NCT01110330 Phase 3 Placebo cream;Ketoconazole 2% cream (formulation F012) (Nizoral);Ketoconazole 2% cream (formulation F126)
23 Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Withdrawn NCT02606383 Phase 3 Dapaconazole;Ketoconazole
24 A Blinded Placebo Controlled Clinical Trial To Evaluate Fungicidal Activity With The Topical Application Of Nitric Oxide Releasing Solution (Nors) In Subjects With Moderate To Severe Tinea Pedis (Athlete's Foot) Completed NCT02871011 Phase 2 Nitric Oxide;Water
25 A Blinded Placebo Controlled Single Cross-over Clinical Trial to Evaluate Fungicidal Activity With Topical Application of 1% Gaseous Nitric Oxide in Subjects With Moderate to Severe Tinea Pedis (Athlete's Foot) Completed NCT00771342 Phase 2 Nitric Oxide;Nitrogen
26 Phase 2 Study - A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration Finding Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Luliconazole Cream 1% in Patients With Tinea Pedis Completed NCT00869336 Phase 2 Luliconazole Cream 1% - 2 wks;Placebo Comparator -2 wks;Luliconazole Cream 1% - 4 wks;Placebo Comparator - 4 wks
27 Three-Arm Trial of Novel Treatment for Tinea Pedis Completed NCT03135912 Phase 2 Experimental Drug SESC 01;Placebo;Terbinafine Hydrochloride
28 An Investigator-blind, Randomized, Multicenter, 5-arm, Placebo- and Active Controlled Parallel Group Pilot Trial to Explore the Efficacy and Tolerability of Topical Bifonazole Liquid Spray in Patients With Athlete's Foot. Completed NCT01013909 Phase 2 Bifonazole spray once daily;Bifonazole spray twice daily;Placebo;Placebo;Lamisil Once
29 A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis Completed NCT00768599 Phase 2 Econazole Nitrate Cream 1%;Econazole Nitrate Foam 1%;Vehicle Foam
30 A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis Completed NCT00893880 Phase 2 1% gaseous Nitric Oxide blended in Oxygen
31 Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis Completed NCT01096472 Phase 2 LAS41003;LAS189961;LAS189962
32 A Multi-Center, Randomized Comparative Study of the Pharmacokinetics of Econazole Nitrate 1% Foam and Econazole Nitrate 1% Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years Completed NCT01696799 Phase 2 Econazole Nitrate;placebo
33 A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis Completed NCT02842021 Phase 2 S2G6T-1;S2G6T-2;S2G6T-3;S2G6T-4
34 Clinical Study Protocol Number DBI-201. Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis Completed NCT04152226 Phase 2 J. Lividum
35 Non-inferiority Phase II Trial Comparing BL123 (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Completed NCT02824926 Phase 2 Dapaconazole;Ketoconazole
36 A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis Completed NCT02860052 Phase 2 SB208 2%;SB208 4%;SB208 16%;Vehicle Gel
37 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam
38 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Moderate to Severe Interdigital Tinea Pedis Completed NCT01891305 Phase 2 VT-1161;placebo
39 EFFICACY AND SAFETY OF A SINGLE-APPLICATION TREATMENT USING TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION TREATMENT USING BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Recruiting NCT03999437 Phase 2 TERBINAFINE HYDROCHLORIDE (1%);BUTENAFINE HYDROCHLORIDE (1%);Vehicle Control
40 A Multicenter, Randomized, Double-Blinded, Parallel Group Comparison Study of the Safety and Efficacy of UHE-103 in Subjects With Moccasin-Type Tinea Pedis Active, not recruiting NCT03897257 Phase 2 UHE-103A1 cream;UHE-103A2 cream;UHE-103B cream;UHE-103A1B cream;UHE-103A2B cream
41 A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects With Distal Subungual Onychomycosis (DSO) of the Toenail Not yet recruiting NCT04188574 Phase 2 BB2603-1;BB2603-3;BB2603-10;Vehicle
42 Phase III Study in Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis Completed NCT01524432 Phase 1 Anti-fungal agent (Clotrimazole) loaded microcapsules;Placebo
43 A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site, Study Comparing Oxiconazole Nitrate Cream 1% (Taro Pharmaceuticals,Inc) to Oxistat® (Oxiconazole Nitrate Cream) Cream 1% (PharmaDerma) in the Treatment of Tinea Pedis Completed NCT01519752 Phase 1 Oxiconazole Nitrate Cream 1%;Oxiconazole Nitrate Cream 1% (Oxistat®);Placebo
44 A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis Completed NCT00835510 Phase 1 Butenafine cream 1% manufactured by Taro;Lotrimin Ultra (butenafine) 1%;Butenafine Vehicle manufactured by Taro
45 A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2%and the Naftin® Cream 2% in Patients With Tinea Pedis Completed NCT02132260 Phase 1 Naftifine Hydrochloride Cream 2%;Naftin® (Naftifine Hydrochloride) Cream 2%;Placebo Topical Cream
46 Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design Study to Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis. Completed NCT01580891 Phase 1 Naftifine HCl Cream 1%;Naftin® (Naftifine HCl) Cream 1%;Placebo topical cream
47 A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis. Completed NCT01580878 Phase 1 Butenafine Hydrochloride Cream, 1%;Lotrimin Ultra®;Butenafine Vehicle
48 A Phase Ib, Randomized, Double Blind, Placebo Controlled Study to Investigate the Pharmacokinetics, Safety and Efficacy of 3 Different Doses of W0027 and Placebo Capsules in Subjects With Clinically and Mycologically Proven MTTP Completed NCT00509275 Phase 1 W0027;Placebo
49 A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® (Naftifine Hydrochloride) Gel 2% in Patients With Tinea Pedis. Completed NCT02335255 Phase 1 Naftifine Hydrochloride Gel 2%;Naftin® Gel 2%;Placebo Topical Gel
50 A Double-Blind, Randomized, Parallel Design Study To Assess the Safety and Pharmacokinetics of Terbinafine Hydrogen Cloride (HCl) Nail Lacquer Applied for 28 Days in Patients With Onychomycosis Completed NCT00691184 Phase 1 Placebo;Terbinafine Hydrochloride;Terbinafine Hydrochloride;Terbinafine

Search NIH Clinical Center for Tinea Pedis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


butenafine
Butenafine hydrochloride
ciclopirox
Ciclopirox olamine
Clioquinol
CLIOQUINOL PWDR
Econazole
Econazole Nitrate
Griseofulvin
Griseofulvin ultramicrosize
haloprogin
Ketoconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
naftifine
Naftifine hydrochloride
oxiconazole
Sodium Hypochlorite
sulconazole
Sulconazole nitrate
terbinafine
Terbinafine hydrochloride
Tolnaftate

Cochrane evidence based reviews: tinea pedis

Genetic Tests for Tinea Pedis

Anatomical Context for Tinea Pedis

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Pedis:

19
Skin Of Foot

MalaCards organs/tissues related to Tinea Pedis:

40
Skin, Testes, Thyroid, Myeloid, T Cells, Neutrophil

Publications for Tinea Pedis

Articles related to Tinea Pedis:

(show top 50) (show all 1290)
# Title Authors PMID Year
1
Consumer preferences of antifungal products for treatment and prevention of tinea pedis. 61 42
30661432 2019
2
Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. 42 61
30768808 2019
3
One Foot After Another-Fungal Foot Issues in Expedition Adventure Racing. 61 42
30718137 2019
4
Characterization of Skin Microbiome in Tinea Pedis. 61
31762504 2019
5
Trichophyton mentagrophytes and T interdigitale genotypes are associated with particular geographic areas and clinical manifestations. 61
31444823 2019
6
Characteristics, Associated Diseases, and Management of Gram-negative Toe-web Infection: A French Experience. 61
31502652 2019
7
Internal environment of footwear is a risk factor for tinea pedis. 61
31436337 2019
8
Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate- and 2,4,6-trinitrophenyl chloride-induced skin inflammation in mice. 61
31724251 2019
9
Syphilis as Athlete's Foot: "The Great Imitator" Strikes Again. 61
31705478 2019
10
Superficial fungal infections. 61
31569324 2019
11
Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population-based study in 161 269 employees. 61
30802934 2019
12
Whole-genome resequencing of Trichophyton rubrum provides insights into population differentiation and drug resistance. 61
31538279 2019
13
[Influence of nutrition, common autoimmune diseases and smoking on the incidence of foot mycoses]. 61
31172201 2019
14
Fangchinoline, a Bisbenzylisoquinoline Alkaloid can Modulate Cytokine-Impelled Apoptosis via the Dual Regulation of NF-κB and AP-1 Pathways. 61
31466313 2019
15
Tinea manuum: A report of 18 cases observed in the metropolitan area of Milan and review of the literature. 61
30929271 2019
16
Structure-based design of δ-lactones for new antifungal drug development: susceptibility, mechanism of action, and toxicity. 61
30734157 2019
17
Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. 61
31321333 2019
18
A Simple Interdigital Separator to Aid the Management of Tinea Pedis. 61
31149595 2019
19
Viability of pathogenic dermatophytes during a 4-week treatment with 1% topical luliconazole for tinea pedis. 61
31111903 2019
20
Reference genes for accurate evaluation of expression levels in Trichophyton interdigitale grown under different carbon sources, pH levels and phosphate levels. 61
30944363 2019
21
The Inhibitory Effect of Essential Oils on Rhizopus stolonifer, Trichophyton mentagrophytes, and Microsporum gypseum. 61
30690523 2019
22
Multiple abscesses in the lower extremities caused by Trichophyton rubrum. 61
30894136 2019
23
Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents. 61
30427072 2019
24
Differences Between Patient-Reported Versus Clinician-Observed Nonulcerative Signs and Symptoms of the Foot in Patients With Diabetes Mellitus. 61
30747799 2019
25
A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level. 61
30456537 2019
26
Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis. 61
31474693 2019
27
Detection of Trichophyton spp. from footwear of patients with tinea pedis. 61
31534072 2019
28
A Case of Tinea Pedis in a Child Caused by Trichophyton interdigitale with Two Different Colony Phenotypes on Primary Culture. 61
31787732 2019
29
Estimated burden of serious human fungal diseases in Turkey. 61
30107069 2019
30
2016 Epidemiological Survey of Dermatomycoses in Japan. 61
31474694 2019
31
Development of a Footwear Sizing System in the National Football League. 61
30048212 2019
32
Influence of the cultivation medium and pH on the pigmentation of Trichophyton rubrum. 61
31504066 2019
33
Hyperhidrosis and its impact on those living with it. 61
30589248 2018
34
Epidemiological and clinical aspects of dermatophytoses in Eastern Slovakia: a retrospective three-year study. 61
30817878 2018
35
Epidemiological Survey of Human Dermatophytosis due to Zoophilic Species in Tehran, Iran. 61
30788309 2018
36
Molecular Epidemiological Analysis of the Spreading Conditions of Trichophyton in Long-Term Care Facilities in Japan. 61
30175735 2018
37
Exoproteome Analysis of Human Pathogenic Dermatophyte Species and Identification of Immunoreactive Proteins. 61
29952123 2018
38
Interdigital melanoma simultaneously affecting two neighboring interdigital spaces : First description in the medical literature. 61
28439743 2018
39
Tinea pedis acquired in mosques? 61
29600810 2018
40
Skin microbiome changes in patients with interdigital tinea pedis. 61
29704463 2018
41
Severe lower limb cellulitis: defining the epidemiology and risk factors for primary episodes in a population-based case-control study. 61
29427797 2018
42
Prevalence and Clinical Correlation of Superficial Fungal Foot Infection in Thai Naval Rating Cadets. 61
29447400 2018
43
Skin Infections. 61
30115333 2018
44
Common Foot Problems: Over-the-Counter Treatments and Home Care. 61
30216025 2018
45
A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis. 61
30124729 2018
46
Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections. 61
29760128 2018
47
Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). 61
30041646 2018
48
[Prevalence of dermatomycoses in professional football players : A study based on data of German Bundesliga fitness check-ups (2013-2015) compared to data of the general population]. 61
29417157 2018
49
Epidemiology of dermatophytoses in 31 municipalities of the province of Buenos Aires, Argentina: A 6-year study. 61
29606407 2018
50
Tatami Mats: A Source of Pitted Keratolysis in a Martial Arts Athlete? 61
29782305 2018

Variations for Tinea Pedis

Expression for Tinea Pedis

Search GEO for disease gene expression data for Tinea Pedis.

Pathways for Tinea Pedis

Pathways related to Tinea Pedis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.67 CLEC7A CLEC6A CLEC4E CARD9
2 11.59 CLEC7A CLEC4E CARD9
3
Show member pathways
11.16 CLEC7A CLEC6A CLEC4E CARD9

GO Terms for Tinea Pedis

Biological processes related to Tinea Pedis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cholesterol biosynthetic process GO:0045540 9.4 SQLE CYP51A1
2 sterol biosynthetic process GO:0016126 9.37 SQLE CYP51A1
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.33 CLEC6A CLEC4E CARD9
4 defense response to fungus GO:0050832 9.32 DCD CLEC6A
5 positive regulation of cytokine secretion GO:0050715 9.26 CLEC6A CLEC4E
6 innate immune response GO:0045087 9.02 TRIM4 CLEC7A CLEC6A CLEC4E CARD9
7 pattern recognition receptor signaling pathway GO:0002221 8.96 CLEC7A CLEC4E

Sources for Tinea Pedis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....